血脂异常基层诊疗指南(实践版·2019)

2019-05-20 中华医学会 中华全科医师杂志.2019.18(5):417-421.

目前我国居民动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)成为首位死亡原因。血脂异常为ASCVD发生发展中最主要的致病性危险因素。美国已经成功降低了冠心病死亡率,其中胆固醇水平的降低贡献最大;而近年中国冠心病死亡率不断增加,首位原因为胆固醇水平升高,占77%。因此,有效控制血脂异常,对我国ASCVD防控具有重要意义。本文为血脂异

中文标题:

血脂异常基层诊疗指南(实践版·2019)

发布机构:

中华医学会

发布日期:

2019-05-20

简要介绍:

目前我国居民动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)成为首位死亡原因。血脂异常为ASCVD发生发展中最主要的致病性危险因素。美国已经成功降低了冠心病死亡率,其中胆固醇水平的降低贡献最大;而近年中国冠心病死亡率不断增加,首位原因为胆固醇水平升高,占77%。因此,有效控制血脂异常,对我国ASCVD防控具有重要意义。本文为血脂异常基层诊疗指南的实践版。 

拓展指南:血脂相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=996290, encodeId=1562996290bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/1dc6d4b1289545db82cfe5a7704a6aac/ec4686c551d845c4a5d6a3be90c2c773.jpg, createdBy=ab972230455, createdName=携手, createdTime=Mon Jul 05 07:02:14 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974964, encodeId=88999e4964f1, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:53 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909823, encodeId=015490982361, content=好好使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e15278865, createdName=1483b45bm86暂无昵称, createdTime=Mon Dec 21 17:49:32 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893901, encodeId=c8a5893901bf, content=(≧ω≦)/, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/3536357c07424f56b878266090ae9920/392e9c1e484c430daa2d0c82ef6df159.jpg, createdBy=52bf5424884, createdName=ms2000000956980985, createdTime=Fri Oct 23 08:01:44 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884601, encodeId=c29f884601c2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5377095, createdName=ms3000001111824950, createdTime=Fri Sep 11 18:38:05 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2021-07-05 携手

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=996290, encodeId=1562996290bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/1dc6d4b1289545db82cfe5a7704a6aac/ec4686c551d845c4a5d6a3be90c2c773.jpg, createdBy=ab972230455, createdName=携手, createdTime=Mon Jul 05 07:02:14 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974964, encodeId=88999e4964f1, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:53 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909823, encodeId=015490982361, content=好好使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e15278865, createdName=1483b45bm86暂无昵称, createdTime=Mon Dec 21 17:49:32 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893901, encodeId=c8a5893901bf, content=(≧ω≦)/, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/3536357c07424f56b878266090ae9920/392e9c1e484c430daa2d0c82ef6df159.jpg, createdBy=52bf5424884, createdName=ms2000000956980985, createdTime=Fri Oct 23 08:01:44 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884601, encodeId=c29f884601c2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5377095, createdName=ms3000001111824950, createdTime=Fri Sep 11 18:38:05 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2021-06-19 ms7000001124466419

    关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=996290, encodeId=1562996290bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/1dc6d4b1289545db82cfe5a7704a6aac/ec4686c551d845c4a5d6a3be90c2c773.jpg, createdBy=ab972230455, createdName=携手, createdTime=Mon Jul 05 07:02:14 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974964, encodeId=88999e4964f1, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:53 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909823, encodeId=015490982361, content=好好使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e15278865, createdName=1483b45bm86暂无昵称, createdTime=Mon Dec 21 17:49:32 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893901, encodeId=c8a5893901bf, content=(≧ω≦)/, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/3536357c07424f56b878266090ae9920/392e9c1e484c430daa2d0c82ef6df159.jpg, createdBy=52bf5424884, createdName=ms2000000956980985, createdTime=Fri Oct 23 08:01:44 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884601, encodeId=c29f884601c2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5377095, createdName=ms3000001111824950, createdTime=Fri Sep 11 18:38:05 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-12-21 1483b45bm86暂无昵称

    好好使用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=996290, encodeId=1562996290bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/1dc6d4b1289545db82cfe5a7704a6aac/ec4686c551d845c4a5d6a3be90c2c773.jpg, createdBy=ab972230455, createdName=携手, createdTime=Mon Jul 05 07:02:14 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974964, encodeId=88999e4964f1, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:53 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909823, encodeId=015490982361, content=好好使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e15278865, createdName=1483b45bm86暂无昵称, createdTime=Mon Dec 21 17:49:32 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893901, encodeId=c8a5893901bf, content=(≧ω≦)/, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/3536357c07424f56b878266090ae9920/392e9c1e484c430daa2d0c82ef6df159.jpg, createdBy=52bf5424884, createdName=ms2000000956980985, createdTime=Fri Oct 23 08:01:44 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884601, encodeId=c29f884601c2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5377095, createdName=ms3000001111824950, createdTime=Fri Sep 11 18:38:05 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-10-23 ms2000000956980985

    (≧ω≦)/

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=996290, encodeId=1562996290bb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/1dc6d4b1289545db82cfe5a7704a6aac/ec4686c551d845c4a5d6a3be90c2c773.jpg, createdBy=ab972230455, createdName=携手, createdTime=Mon Jul 05 07:02:14 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974964, encodeId=88999e4964f1, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:53 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909823, encodeId=015490982361, content=好好使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e15278865, createdName=1483b45bm86暂无昵称, createdTime=Mon Dec 21 17:49:32 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893901, encodeId=c8a5893901bf, content=(≧ω≦)/, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/3536357c07424f56b878266090ae9920/392e9c1e484c430daa2d0c82ef6df159.jpg, createdBy=52bf5424884, createdName=ms2000000956980985, createdTime=Fri Oct 23 08:01:44 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884601, encodeId=c29f884601c2, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74ab5377095, createdName=ms3000001111824950, createdTime=Fri Sep 11 18:38:05 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-11 ms3000001111824950

    谢谢

    0